GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » Float Percentage Of Total Shares Outstanding

XTL Biopharmaceuticals (XTAE:XTLB) Float Percentage Of Total Shares Outstanding : 75.84% (As of Jun. 05, 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, XTL Biopharmaceuticals's float shares is 413.26 Mil. XTL Biopharmaceuticals's total shares outstanding is 544.91 Mil. XTL Biopharmaceuticals's float percentage of total shares outstanding is 75.84%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, XTL Biopharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, XTL Biopharmaceuticals's Institutional Ownership is 0.09%.

XTL Biopharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

XTL Biopharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=413.26/544.91
=75.84%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals (XTAE:XTLB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
XTAE:CANF XTAE:PPBT XTAE:CBI XTAE:MTLF XTAE:KDST XTAE:BOLT XTAE:PLNT XTAE:HDST-M XTAE:DNA XTAE:GFC-M OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
XTLB:USA H2K2:Germany
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
Website
https://www.xtlbio.com
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.